Sector News

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

February 26, 2015
Life sciences
So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.
 
The California company, which boasts a market value of almost $15 billion, is exploring its options–and those include a sale, Bloomberg’s sources say. While deliberations are still in the early stages, Pharmacyclics already reportedly has some big-name suitors circling, including Johnson & Johnson and Novartis.
 
While a potential deal for the Sunnyvale-based company–which could draw bids as high as $17 billion or $18 billion, Bloomberg notes–would be the biggest in the industry so far this year, it’s nothing the pharma giants couldn’t swallow. And drugmakers may be eager to get their hands on Imbruvica, the blood cancer drug that last month scored its fourth FDA approval.
 
For J&J, the fit would be natural. Its Janssen subsidiary already markets the med outside the U.S. and shares marketing duties with Pharmacyclics at home, and the pair is working together to try to expand Imbruvica’s patient pool. But J&J isn’t the company’s only partner; it’s also teamed up with drugmakers the likes of Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene and Roche  to study Imbruvica as part of cancer-fighting combos.
 
And for Novartis, which already boasts a pair of blood-cancer powerhouse treatments in Gleevec and Tasigna, the pickup makes sense, too. The Basel-based pharma giant has been active in the M&A arena as it rides pharma’s slim-down wave, shedding non-core assets and working to strengthen its focus areas. Cancer is high on its priority list, and to that end, it last year agreed to fork over $16 billion in exchange for GlaxoSmithKline’s oncology business–a deal GSK is set to close next week.
 
By Carly Helfand
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.